Microfluidic particle synthesis has become a practical route for producing particles with controllable size, shape, composition, internal structure, and surface chemistry—qualities essential for drug delivery, diagnostics, imaging, biosensing, catalysis, and advanced materials. Conventional batch synthesis often struggles with inconsistent mixing, uncontrolled nucleation/growth, poor batch-to-batch reproducibility, and difficult scale-up. Microfluidic systems address these issues by enabling rapid, predictable mixing and well-defined residence times in precisely engineered microchannels or droplet templates.
At Creative Biolabs, we combine microfluidic design and manufacturing expertise with particle engineering know-how to build a "design–build–test–iterate" workflow. Whether you want nanoparticles (10–500 nm) for advanced delivery or microparticles (1–1000 μm) for sustained release, cell encapsulation, or functional materials, we tailor the chip architecture, materials, and operating conditions to meet your performance targets.
Service Portfolio Overview
Our particle synthesis services span two core microfluidic production paradigms—often used independently or in combination:
1) Continuous-Flow Formation (Mixing-Controlled)
Best for nanoparticle and vesicle systems where particle properties are highly sensitive to mixing kinetics and solvent exchange. Typical use cases include lipid/liposome systems and polymer nanoparticles.
2) Droplet Templating (Emulsion & Microgel-Driven)
Best for microparticles and hydrogel beads where you want droplet-to-particle conversion through crosslinking, polymerization, curing, or gelation. Typical use cases include hydrogels, alginate particles, polyacrylamide particles, polymer microparticles, and Janus micro-particles.
Lipid and liposome systems are vesicular structures formed by one or more lipid bilayer membranes that encapsulate an aqueous volume and are widely used as drug and gene delivery vehicles. Conventional methods can suffer from complex workflows, low encapsulation efficiency, and polydisperse size distributions. Microfluidics enables controlled self-assembly by adjusting flow rates, cross-flow ratios, lipid composition, and concentration—supporting tunable particle sizes and narrower size distributions.
Hydrogels are cross-linked 3D networks of hydrophilic polymer chains with high water content, tissue-like elastic properties, and biocompatibility. They are attractive for encapsulation of drugs/cells and tissue engineering applications. Microfluidics is an enabling tool for generating shape-controlled hydrogels (e.g., microparticles, microfibers, building blocks) and can support continuous production with high monodispersity in suitable designs.
Alginate is a natural, biocompatible carbohydrate-based hydrogel material often used as a drug carrier, encapsulation matrix, or scaffold material due to biocompatibility, biodegradability, and availability. Microfluidic on-chip synthesis can help resolve limitations of traditional approaches and enable micrometer-sized particles with controllable size and functionality.
Polyacrylamide (PAM) is a hydrogel material composed of a loosely cross-linked acrylamide structure and has been used in biomaterial applications such as soft contact lenses, implants, and drug delivery particle systems. Due to ease of surface functionalization, PAM has also been used in microencapsulation applications. The service describes microfluidics as a method to produce polyacrylamide particles in the tens to hundreds of microns range (e.g., ~20–220 μm) and notes utility for producing soft deformable beads relevant to assays that load discrete objects (e.g., particles/cells).
Polymer nanoparticles have attracted attention in disease treatment and drug delivery contexts. Microfluidic synthesis supports controlled formation of nanoparticulate systems and emphasizes high batch-to-batch consistency as a service advantage. The service describes two broad forms—nanocapsules (oily core + polymer shell) and nanospheres (polymer networks).
Polymer microparticles are biomaterials typically in the 1–1000 μm size range and are widely used in therapeutic applications as drug delivery strategies, offering stability and reproducibility and often not requiring removal from the body (application dependent). Microfluidics can provide better control over droplet templates that define microparticle size.
Janus particles are asymmetric (non-centrosymmetric) materials with distinct properties across domains (morphology/composition/performance), enabling unique applications such as purification, targeted delivery, theranostics, multiplexing, and detection (application dependent). Creative Biolabs positions this service around monodisperse Janus products and high control through suitable generators and mature chip design concepts.
Partner With Us
Client Testimonials
"We had a persistent batch-to-batch shift in nanoparticle size that was impacting our in vivo consistency. The microfluidic workflow delivered a tighter distribution and, more importantly, a process window we could reproduce week after week."
— Senior Scientist, Drug Delivery
"Creative Biolabs didn't just provide a chip—they provided an end-to-end synthesis and characterization package. The documentation was clean, the datasets were usable, and their optimization approach was systematic rather than trial-and-error."
— R&D Manager, Advanced Formulations
"Our liposome preparation was time-consuming and highly operator-dependent. After moving to microfluidics, we saw faster iteration across composition and flow conditions, and the results were much easier to replicate."
— Formulation Lead, Nucleic Acid Delivery
"We were working with expensive materials and could not afford large screening volumes. Microfluidics dramatically reduced consumption while enabling broader parameter exploration. The value wasn't just particle quality—it was speed."
— Materials Scientist, Functional Polymers
"We needed hydrogel microgels with consistent size for a proof-of-concept encapsulation study. The droplet templating strategy produced uniform particles and helped us explore crosslinking conditions without wasting reagents."
— Principal Investigator, Translational Research
Fig.1 Schematic diagram of the microfluidic chip.1,2
